Simultaneous determination of serum flecainide and its metabolites by using high performance liquid chromatography. 2004

Kosuke Doki, and Masato Homma, and Keisuke Kuga, and Shigeyuki Watanabe, and Iwao Yamaguchi, and Yukinao Kohda
Department of Pharmaceutical Sciences, Institute of Clinical Medicine, University of Tsukuba, Ten-nodai 1-1-1, Tsukuba, Ibaraki 305-8575, Japan.

Simultaneous determination of serum flecainide and its oxidative metabolites was carried out by using high performance liquid chromatography (HPLC) equipped with conventional octadecylsilyl silica (ODS) column and fluorescence detector. Flecainide and its metabolites, m-O-dealkylated flecainide (MODF) and m-O-dealkylated lactam of flecainide (MODLF) in serum were extracted with ethyl acetate. The recoveries of flecainide, MODF and MODLF were greater than 92, 93, and 60% with the coefficient of variations (CVs) less than 3.2, 5.8, and 5.3%, respectively. The calibration curves were linear at the concentration range of 50-1500 ng/mL for flecainide and 10-500 ng/mL for MODF and MODLF (r > 0.999). The CVs for intra-day assay were 2.7-5.3% for flecainide, 3.0-4.2% for MODF, and 3.7-4.3% for MODLF, respectively. The CVs for inter-day assay were 7.0-8.4% for flecainide, 3.3-6.7% for MODF, and 4.4-7.7% for MODLF, respectively. This assay method can be used for assessing the metabolic ability of flecainide in the patients with tachyarrhythmia.

UI MeSH Term Description Entries
D008297 Male Males
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D005260 Female Females
D005424 Flecainide A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS. Flecainide Acetate,Apocard,Flecadura,Flecainid-Isis,Flecainide Monoacetate,Flecainide Monoacetate, (+-)-Isomer,Flecainide Monoacetate, (R)-Isomer,Flecainide Monoacetate, (S)-Isomer,Flecainide, (R)-Isomer,Flecainide, (S)-Isomer,Flecainide, 5-HO-N-(6-oxo)-Derivative,Flecainide, 5-HO-N-(6-oxo)-Derivative, (+-)-Isomer,Flecatab,Flécaïne,R818,Tambocor,Flecainid Isis
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000889 Anti-Arrhythmia Agents Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. Anti-Arrhythmia Agent,Anti-Arrhythmia Drug,Anti-Arrhythmic,Antiarrhythmia Agent,Antiarrhythmia Drug,Antiarrhythmic Drug,Antifibrillatory Agent,Antifibrillatory Agents,Cardiac Depressant,Cardiac Depressants,Myocardial Depressant,Myocardial Depressants,Anti-Arrhythmia Drugs,Anti-Arrhythmics,Antiarrhythmia Agents,Antiarrhythmia Drugs,Antiarrhythmic Drugs,Agent, Anti-Arrhythmia,Agent, Antiarrhythmia,Agent, Antifibrillatory,Agents, Anti-Arrhythmia,Agents, Antiarrhythmia,Agents, Antifibrillatory,Anti Arrhythmia Agent,Anti Arrhythmia Agents,Anti Arrhythmia Drug,Anti Arrhythmia Drugs,Anti Arrhythmic,Anti Arrhythmics,Depressant, Cardiac,Depressant, Myocardial,Depressants, Cardiac,Depressants, Myocardial,Drug, Anti-Arrhythmia,Drug, Antiarrhythmia,Drug, Antiarrhythmic,Drugs, Anti-Arrhythmia,Drugs, Antiarrhythmia,Drugs, Antiarrhythmic
D012680 Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed) Specificity,Sensitivity,Specificity and Sensitivity
D015203 Reproducibility of Results The statistical reproducibility of measurements (often in a clinical context), including the testing of instrumentation or techniques to obtain reproducible results. The concept includes reproducibility of physiological measurements, which may be used to develop rules to assess probability or prognosis, or response to a stimulus; reproducibility of occurrence of a condition; and reproducibility of experimental results. Reliability and Validity,Reliability of Result,Reproducibility Of Result,Reproducibility of Finding,Validity of Result,Validity of Results,Face Validity,Reliability (Epidemiology),Reliability of Results,Reproducibility of Findings,Test-Retest Reliability,Validity (Epidemiology),Finding Reproducibilities,Finding Reproducibility,Of Result, Reproducibility,Of Results, Reproducibility,Reliabilities, Test-Retest,Reliability, Test-Retest,Result Reliabilities,Result Reliability,Result Validities,Result Validity,Result, Reproducibility Of,Results, Reproducibility Of,Test Retest Reliability,Validity and Reliability,Validity, Face
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular

Related Publications

Kosuke Doki, and Masato Homma, and Keisuke Kuga, and Shigeyuki Watanabe, and Iwao Yamaguchi, and Yukinao Kohda
June 1984, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan,
Kosuke Doki, and Masato Homma, and Keisuke Kuga, and Shigeyuki Watanabe, and Iwao Yamaguchi, and Yukinao Kohda
March 1992, Journal of chromatography,
Kosuke Doki, and Masato Homma, and Keisuke Kuga, and Shigeyuki Watanabe, and Iwao Yamaguchi, and Yukinao Kohda
May 1985, Pharmaceutical research,
Kosuke Doki, and Masato Homma, and Keisuke Kuga, and Shigeyuki Watanabe, and Iwao Yamaguchi, and Yukinao Kohda
March 1981, Journal of chromatography,
Kosuke Doki, and Masato Homma, and Keisuke Kuga, and Shigeyuki Watanabe, and Iwao Yamaguchi, and Yukinao Kohda
May 1991, Journal of chromatography,
Kosuke Doki, and Masato Homma, and Keisuke Kuga, and Shigeyuki Watanabe, and Iwao Yamaguchi, and Yukinao Kohda
January 2004, Journal of analytical toxicology,
Kosuke Doki, and Masato Homma, and Keisuke Kuga, and Shigeyuki Watanabe, and Iwao Yamaguchi, and Yukinao Kohda
May 1981, Journal of chromatography,
Kosuke Doki, and Masato Homma, and Keisuke Kuga, and Shigeyuki Watanabe, and Iwao Yamaguchi, and Yukinao Kohda
April 1979, Journal of chromatography,
Kosuke Doki, and Masato Homma, and Keisuke Kuga, and Shigeyuki Watanabe, and Iwao Yamaguchi, and Yukinao Kohda
February 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences,
Kosuke Doki, and Masato Homma, and Keisuke Kuga, and Shigeyuki Watanabe, and Iwao Yamaguchi, and Yukinao Kohda
November 1997, Journal of chromatography. B, Biomedical sciences and applications,
Copied contents to your clipboard!